{
  "source": "PA-Notification-Pemazyre.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1316-6\nProgram Prior Authorization/Notification\nMedication Pemazyre® (pemigatinib)\nP&T Approval Date 6/2020, 6/2021, 6/2022, 10/2022, 10/2023, 10/2024\nEffective Date 1/1/2025\n1. Background:\nPemazyre (pemigatinib) is a kinase inhibitor indicated for the treatment of adults with previously\ntreated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth\nfactor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.\nThis indication is approved under accelerated approval based on overall response rate and\nduration of response. Continued approval for this indication may be contingent upon verification\nand description of clinical benefit in a confirmatory trial(s). Pemazyre is also indicated for the\ntreatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with\nFGFR1 rearrangement.\nThe National Cancer Comprehensive Network (NCCN) also recommends use of Pemazyre for the\ntreatment of myeloid/lymphoid/mixed lineage neoplasms with eosinophilia and FGFR1\nrearrangement.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Pemazyre will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Cholangiocarcinoma\n1. Initial Authorization\na. Pemazyre will be approved based on all of the following criteria:\n(1) Diagnosis of cholangiocarcinoma\n© 2024 UnitedHealth",
    "ill be issued for 12 months.\nB. Cholangiocarcinoma\n1. Initial Authorization\na. Pemazyre will be approved based on all of the following criteria:\n(1) Diagnosis of cholangiocarcinoma\n© 2024 UnitedHealthcare Services, Inc.\n1\n-AND-\n(2) Disease is one of the following:\na. Unresectable locally advanced\nb. Resected gross residual (R2)\nc. Metastatic\n-AND-\n(3) Disease has presence of a fibroblast growth factor receptor 2 (FGFR2) fusion or\nother rearrangement\n-AND-\n(4) Patient has been previously treated\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Pemazyre will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Pemazyre\ntherapy\nAuthorization will be issued for 12 months.\nC. Myeloid/Lymphoid Neoplasms\n1. Initial Authorization\na. Pemazyre will be approved based on both of the following criteria:\n(1) Diagnosis of myeloid/lymphoid/mixed lineage neoplasms with eosinophilia\n-AND-\n(2) Presence of an FGFR1 rearrangement\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Pemazyre will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Pemazyre\ntherapy\n© 2024 UnitedHealthcare Services, Inc.\n2\nAuthorization will be issued for 12 months.\nD. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim lo",
    "inical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Pemazyre® [package insert]. Wilmington, DE: Incyte Corporation. June 2023.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org. Accessed August 28, 2024.\nProgram Prior Authorization/Notification – Pemazyre® (pemigatinib)\nChange Control\n6/2020 New program.\n6/2021 Annual review. Addition of coverage criteria for myeloid/lymphoid\nneoplasms according to NCCN. Updated background and references.\n6/2022 Annual review. Revised grammar in criteria with no changes to clinical\nintent. Updated background with conditional approval language per\nprescribing information. Updated references.\n10/2022 Updated criteria and background based on newly approved indication\nfor myeloid/lymphoid neoplasms. Updated reference. Added state\nmandate footnote.\n10/2023 Annual review. Updated criteria for Myeloid/Lymphoid Neoplasms.\nUpdated references.\n10/2024 Annual review. Updated criteria for cholangiocarcinoma.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}